Search Results - "F RAHAGHI, FRANCK"

Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what’s down the road? by Rahaghi, Franck F.

“…Intravenous infusion of alpha-1 antitrypsin (AAT) was approved by the United States Food and Drug Administration (FDA) to treat emphysema associated with AAT…”
Get full text

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence by Rahaghi, Franck F, Miravitlles, Marc

“…Alpha-1 antitrypsin deficiency (AATD) is a common hereditary disorder caused by mutations in the SERPINA1 gene, which encodes alpha-1 antitrypsin (AAT; also…”
Get full text

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease by Rahaghi, Franck F, Hsu, Vivien M, Kaner, Robert J, Mayes, Maureen D, Rosas, Ivan O, Saggar, Rajan, Steen, Virginia D, Strek, Mary E, Bernstein, Elana J, Bhatt, Nitin, Castelino, Flavia V, Chung, Lorinda, Domsic, Robyn T, Flaherty, Kevin R, Gupta, Nishant, Kahaleh, Bashar, Martinez, Fernando J, Morrow, Lee E, Moua, Teng, Patel, Nina, Shlobin, Oksana A, Southern, Brian D, Volkmann, Elizabeth R, Khanna, Dinesh

“…Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and…”
Get full text

Clinical phenotyping: role in treatment decisions in sarcoidosis by Baughman, Robert P, Scholand, Mary Beth, Rahaghi, Franck F

“…A variety of phenotypic categorisations have been developed for sarcoidosis. Phenotyping has been used for genetics studies and to guide treatment selection…”
Get full text

Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study by Rahaghi, Franck F, Sweiss, Nadera J, Saketkoo, Lesley Ann, Scholand, Mary Beth, Barney, Joseph B, Gerke, Alicia K, Lower, Elyse E, Mirsaeidi, Mehdi, O'Hare, Lanier, Rumbak, Mark J, Samavati, Lobelia, Baughman, Robert P

“…In patients treated with repository corticotrophin injection (RCI) for pulmonary sarcoidosis, effective management of adverse events may improve adherence…”
Get full text

Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study by Rahaghi, Franck F, Safdar, Zeenat, Brown, Anne Whitney, de Andrade, Joao A, Flaherty, Kevin R, Kaner, Robert J, King, Christopher S, Padilla, Maria L, Noth, Imre, Scholand, Mary Beth, Shifren, Adrian, Nathan, Steven D

“…In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing…”
Get full text

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil by Kingrey, John F, Miller, Chad E, Franco, Veronica, Smith, Jimmy S, Zolty, Ronald, Oudiz, Ronald J, Elwing, Jean M, Huston, Jessica H, Melendres-Groves, Lana, Ravichandran, Ashwin, Balasubramanian, Vijay, Wu, Benjamin, Hwang, Stephanie, Seaman, Scott, Broderick, Meredith, Rahaghi, Franck F

“…Treprostinil is a prostacyclin analogue that targets multiple cellular receptors to treat pulmonary arterial hypertension (PAH). In certain scenarios, patients…”
Get full text

Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi study by Asif, Huda, Rahaghi, Franck F, Ohsumi, Akihiro, Philley, Julie, Emtiazjoo, Amir, Hirama, Takashi, Baker, Arthur W, Shu, Chin-Chung, Silveira, Fernanda, Poulin, Vincent, Rizzuto, Pete, Nagao, Miki, Burgel, Pierre-Régis, Hays, Steve, Aksamit, Timothy, Kawasaki, Takeshi, Dela Cruz, Charles, Aliberti, Stefano, Nakajima, Takahiro, Ruoss, Stephen, Marras, Theodore K, Snell, Gregory I, Winthrop, Kevin, Mirsaeidi, Mehdi

“…Nontuberculous mycobacterial (NTM) diseases are difficult-to-treat infections, especially in lung transplant (LTx) candidates. Currently, there is a paucity of…”
Get full text

A 76-Year-Old-Man With Dyspnea and Abnormal Oximetry Run by Williams, Veronica, Rahaghi, Franck F., Drexler, Ian R., Sakr, Lewjain

“…A 76-year-old male Vietnam veteran with a medical history of OSA on CPAP, mild COPD, Parsonage-Turner syndrome (a rare neurologic syndrome manifesting with…”
Get full text

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat by Rahaghi, Franck F., Balasubramanian, Vijay P., Bourge, Robert C., Burger, Charles D., Chakinala, Murali M., Eggert, Michael S., Elwing, Jean M., Feldman, Jeremy, King, Christopher, Klinger, James R., Mathai, Stephen C., McConnell, John Wesley, Palevsky, Harold I., Restrepo‐Jaramillo, Ricardo, Safdar, Zeenat, Sager, Jeffrey S., Sood, Namita, Sulica, Roxana, White, R. James, Hill, Nicholas S.

“…Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with…”
Get full text

Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation by Rahaghi, Franck F., Feldman, Jeremy P., Allen, Roblee P., Tapson, Victor, Safdar, Zeenat, Balasubramanian, Vijay P., Shapiro, Shelley, Mathier, Michael A., Elwing, Jean M., Chakinala, Murali M., White, R. James

“…Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was…”
Get full text

The role of riociguat in combination therapies for pulmonary arterial hypertension by Rahaghi, Franck F., Trivieri, Maria Giovanna, Sahay, Sandeep

“…Effective clinical decision-making in initial treatment selection and switching or escalations of therapy for pulmonary arterial hypertension (PAH) depends on…”
Get full text

Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial by Baughman, Robert P, Shlobin, Oksana A, Gupta, Rohit, Engel, Peter J, Stewart, Jeffrey I, Lower, Elyse E, Rahaghi, Franck F, Zeigler, Joyce, Nathan, Steven D

“…Riociguat is effective in delaying the time to clinical worsening (TCW) in patients with groups 1 and 4 pulmonary hypertension. Is riociguat more effective…”
Get full text

Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study by Rahaghi, Franck F, Kolaitis, Nicholas A, Adegunsoye, Ayodeji, de Andrade, Joao A, Flaherty, Kevin R, Lancaster, Lisa H, Lee, Joyce S, Levine, Deborah J, Preston, Ioana R, Safdar, Zeenat, Saggar, Rajan, Sahay, Sandeep, Scholand, Mary Beth, Shlobin, Oksana A, Zisman, David A, Nathan, Steven D

“…Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) and is associated with worse outcomes and increased mortality…”
Get full text

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document by Rahaghi, Franck F., Alnuaimat, Hassan M., Awdish, Rana L.A., Balasubramanian, Vijay P., Bourge, Robert C., Burger, Charles D., Butler, John, Cauthen, C. Gregory, Chakinala, Murali M., deBoisblanc, Bennett P., Eggert, Michael S., Engel, Peter, Feldman, Jeremy, McConnell, J. Wesley, Park, Myung, Sager, Jeffrey S., Sood, Namita, Palevsky, Harold I.

“…In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or…”
Get full text

Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging Therapy by Perez, Vanessa C, Williams, Veronica, Rahaghi, Franck F

“…Oral treprostinil, approved for the treatment of pulmonary arterial hypertension, remains an attractive option in combination with other medications to delay…”
Get full text

Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis by Rahaghi, Franck F, Baughman, Robert P, Saketkoo, Lesley Ann, Sweiss, Nadera J, Barney, Joseph B, Birring, Surinder S, Costabel, Ulrich, Crouser, Elliott D, Drent, Marjolein, Gerke, Alicia K, Grutters, Jan C, Hamzeh, Nabeel Y, Huizar, Isham, Ennis James, 4th, W, Kalra, Sanjay, Kullberg, Susanna, Li, Huiping, Lower, Elyse E, Maier, Lisa A, Mirsaeidi, Mehdi, Müller-Quernheim, Joachim, Carmona Porquera, Eva M, Samavati, Lobelia, Valeyre, Dominique, Scholand, Mary Beth

“…Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive…”
Get full text

Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension by Hill, Nicholas S, Rahaghi, Franck F, Sood, Namita, Frey, Reiner, Ghofrani, Hossein-Ardeschir

“…Abstract Riociguat is a soluble guanylate cyclase stimulator that has been approved for the treatment of pulmonary arterial hypertension and inoperable chronic…”
Get full text

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry by Rahaghi, Franck F, Monk, Richard, Ramakrishnan, Viswanathan, Beiko, Tatsiana, Strange, Charlie

“…The extent of the survival benefit of augmentation therapy for alpha-1 antitrypsin deficiency (AATD) in individuals with advanced COPD is difficult to define…”
Get full text

Inpatient Initiation of Oral Treprostinil in an Academic Medical System by Hohlfelder, Benjamin, Tonelli, Adriano R., Heresi, Gustavo A., Bair, Nancy, Rahaghi, Franck F., Bauer, Seth R.

“…Purpose Clinicians may transition patients on parenteral or inhaled prostacyclins to oral treprostinil for ease of use or to avoid adverse effects related to…”
Get full text